Table 1.
Estimates of the 4 Stages of the Continuum of Human Immunodeficiency Virus care for 2016 in 11 European Countries by Key Population and Sex
| Country | Population | PLHIV [95% CI] | % Diagnosed [Estimated Range] | % Ever Treated [Estimated Range] | % Suppresseda [Estimated Range] | % Suppressed of PLHIV [Estimated Range] |
|---|---|---|---|---|---|---|
| Austria | ||||||
| MSM | 2920 [2781–3058] | 92.8 [88.6–97.4] | 93.9 [90.2–97.6] | 86.1 [77.3–95.0] | 75.0 [64.2–86.7] | |
| PWID | 1030 [997–1062] | 96.8 [93.9–100] | 92.8 [88.0–97.6] | 81.7 [74.9–88.4] | 73.4 [61.5–86.1] | |
| Heterosexualsb | 2786 [2648–2989] | 91.2 [85.0–95.9] | 95.0 [91.4–98.7] | 86.2 [78.5–93.9] | 74.7 [64.6–87.3] | |
| Men | 5338 [5134–5542] | 91.9 [88.5–95.6] | 93.2 [88.8–97.7] | 85.0 [76.4–93.6] | 72.8 [62.9–83.2] | |
| Women | 1739 [1631–1846] | 93.8 [88.4–100] | 94.0 [89.8–98.3] | 85.6 [78.5–92.7] | 75.5 [64.7–87.5] | |
| Total | 7079 [6946–7330] | 92.3 [89.2–94.1] | 93.4 [89.0–97.8] | 85.2 [76.9–93.4] | 73.4 [65.0–83.4] | |
| Croatia | ||||||
| MSM | 1112 [1012–1268] | 69.6 [61.0–76.5] | 95.9 [93.9–97.9] | 92.3 [90.6–94.1] | 61.6 [60.5–62.7] | |
| Total | 1488 [1356–1708] | 74.1 [64.5–81.3] | 96.2 [94.2–98.2] | 92.1 [90.2–94.1] | 65.7 [64.2–67.0] | |
| Denmark | ||||||
| MSM | 2934 [2598–3270] | 88.5 [79.4–100] | 98.4 [98.1–98.8] | 97.6 [97.1–98.2] | 85.1 [84.6–85.6] | |
| PWID | 452 [411–567] | 90.7 [72.3–99.8] | 95.0 [93.3–96.6] | 92.0 [89.8–94.1] | 79.3 [81.1] | |
| Heterosexuals | 2454 [1997–2919] | 94.2 [88.3–100] | 97.7 [97.2–98.2] | 94.7 [93.4–96.1] | 86.8 [85.1–88.0] | |
| Men | 4706 [4342–5269] | 90.1 [80.5–97.6] | 97.2 [96.7–97.6] | 96.8 [95.8–97.7] | 84.7 [83.8–85.5] | |
| Women | 1704 [1536–1872] | 90.1 [82.1–100] | 97.2 [96.7–97.6] | 93.6 [92.3–94.9] | 82.0 [80.8–83.1] | |
| Total | 6233 [5775–6690] | 92.7 [86.3–100] | 97.2 [96.7–97.6] | 95.9 [94.8–97.0] | 86.4 [85.4–87.3] | |
| France | ||||||
| MSM | 64 900 [63 600–66 200] | 85.9 [84.7–87.3] | 90.6 [85.9–91.9] | 96.8 [96.5–96.9] | 75.3 [74.6–76.0] | |
| PWID | 11 900 [11 500–12 300] | 97.4 [96.3–98.1] | 90.6 [87.2–93.9] | 95.3 [94.7–95.9] | 83.7 [82.0–86.2] | |
| Heterosexuals | 95 700 [93 500–98 100] | 84.9 [83.2–86.7] | 89.4 [88.6–90.3] | 93.9 [93.7–94.2] | 71.3 [70.8–71.8] | |
| Men | 115 600 [113 700–117 300] | 85.1 [84.0–86.4] | 89.8 [89.0–90.5] | 95.6 [95.5–95.8] | 73.1 [72.8–73.5] | |
| Women | 57 000 [56 000–57 900] | 88.2 [87.3–89.4] | 89.5 [88.1–90.9] | 93.8 [93.5–94.0] | 74.0 [73.2–74.9] | |
| Total | 172 700 [170 800–174 500] | 86.1 [85.2–87.1] | 89.7 [89.6–89.8] | 95.0 [94.9–95.2] | 73.4 [73.2–73.5] | |
| Germany | ||||||
| MSM | 545,00 [51 200–58 300] | 85.1 [85.1–90.6] | 94.2 [90.6–97.8] | 93.3 [90.2–96.5] | 74.8 [72.3–77.4] | |
| PWID | 8,800 [7,900–9,700] | 89.7 [81.4–100] | 91.8 [86.1–97.4] | 81.8 [75.0–88.5] | 67.4 [61.8–72.9] | |
| Heterosexuals | 18 500 [16 800–20 200] | 87.6 [80.2–96.4] | 94.7 [91.3–98.0] | 89.2 [86.1–92.3] | 74.0 [71.4–76.5] | |
| Men | 66 100 [61 400–71 200] | 85.8 [79.6–92.3] | 93.8 [90–97.5] | 91.7 [88.2–95.2] | 73.8 [71.0–76.6] | |
| Women | 15 600 [14 000–17 100] | 88.5 [80.7–98.6] | 94.4 [90.8–98.0] | 87.3 [83.5–91.2] | 72.9 [69.7–76.2] | |
| Total | 82 900 [77 100–89 400] | 86.6 [80.3–93.1] | 93.9 [90.2–97.6] | 90.8 [87.2–94.3] | 73.8 [70.9–76.7] | |
| Greece | ||||||
| MSM | 6767 [6519–7066] | 88.5 [84.8–91.9] | 89.0 [85.4–92.4] | 84.4 [80.1–88.7] | 66.5 [63.1–69.9] | |
| PWID | 2156 [2027–2336] | 59.9 [55.3–63.7] | 81.2 [74.1–88.3] | 73.7 [68.6–78.8] | 35.9 [33.4–38.3] | |
| Heterosexuals | 4406 [3922–4889] | 73.8 [66.5–82.9] | 91.3 [88.7–93.8] | 79.6 [69.7–89.5] | 53.6 [47.0–60.3] | |
| Men | 11 040 [10 627–11 624] | 79.7 [75.7–82.8] | 88.2 [84.2–92.1] | 82.2 [76.5–87.8] | 57.8 [53.8–61.8] | |
| Women | 2404 [2135–2680] | 72.0 [64.6–81.0] | 87.1 [82.0–92.2] | 79.5 [70.5–88.4] | 49.8 [44.2–55.4] | |
| Total | 12 953 [12 582–13 619] | 81.3 [77.3–83.7] | 88.3 [84.4–92.1] | 81.8 [75.6–87.9] | 58.7 [54.3–63.1] | |
| Italy | ||||||
| MSM | 48 458 | 83.9 | 88.7 [85.5–91.9] | 92.4 [91.2–93.5] | 68.8 [67.9–69.6] | |
| PWID | 26 481 | 95.9 | 85.3 [78.5–92.1] | 84.5 [78.3–90.7] | 69.1[64.0–74.2] | |
| Heterosexuals | 57 569 | 86.7 | 91.8 [89.0–94.6] | 89.6 [87.4–91.7] | 71.3 [69.6–73.0] | |
| Men | 104 255 | 86.7 | 89.2 [85.7–92.8] | 91.2 [89.1–93.2] | 70.6 [68.9–72.1] | |
| Women | 36 397 | 91.7 | 90.2 [86.4–94.0] | 86.4 [83.3–89.6] | 71.4 [68.9–74.1] | |
| Total | 140 652 | 88.0 | 89.4 [85.9–93.0] | 90.1 [87.8–92.4] | 70.9 [69.1–72.7] | |
| Netherlands | ||||||
| MSM | 13 876 [13 674–14 127] | 89.8 [88.2–91.1] | 97.8 [97.4–98.2] | 96.8 [95.7–97.9] | 84.4 [83.4–85.3] | |
| PWID | 360 [358–364] | 98.6 [97.5–99.2] | 96.7 [94.9–98.4] | 92.0 [88.1–95.8] | 87.5 [83.9–91.4] | |
| Heterosexuals | 7557 [7362–7757] | 87.6 [85.3–89.9] | 97.0 [96.0–97.9] | 92.4 [89.7–95.2] | 78.5 [76.2–80.1] | |
| Men | 18 588 [18 327–18 995] | 88.2 [86.3–89.5] | 97.5 [96.9–98.2] | 95.9 [94.2–96.9] | 81.6 [80.3–83.0] | |
| Women | 4257 [4157–4396] | 91.3 [88.4–93.5] | 97.1 [96.3–98.0] | 92.1 [89.5–94.8] | 80.6 [78.3–82.9] | |
| Total | 22 845 [22 530–23 269] | 88.8 [87.2–90.0] | 97.5 [96.8–98.1] | 95.1 [93.3–96.9] | 82.4 [80.8–83.9] | |
| Spain | ||||||
| MSM | 58 936 [56 222–63 156] | 83.5 [78.4–86.6] | 92.9 [91.3–94.6] | 88.6 [83.3–93.8] | 68.7 [64.6–72.7] | |
| PWID | 20 278 [20 091–20 614] | 97.6 [96.0–98.5] | 86.4 [82.0–90.8] | 79.2 [69.6–88.9] | 66.8 [58.7–75.0] | |
| Heterosexuals | 30 404 [28 620–32 270] | 83.0 [79.4–86.2] | 93.3 [91.0–95.6] | 83.9 [76.5–91.3] | 64.9 [59.2–70.7] | |
| Men | 119 937 [110 455–131 380] | 86.2 [82.3–88.8] | 92.5 [90.5–94.5] | 87.3 [81.3–93.2] | 69.6 [64.8–74.3] | |
| Women | 26 559 [23 962–29 527] | 86.3 [77.6–95.6] | 92.2 [89.7–94.6] | 82.6 [74.7–90.4] | 65.7 [59.4–71.9] | |
| Total | 146 500 [134 417–160 908] | 86.3 [82.1–88.8] | 92.5 [90.4–94.5] | 86.5 [80.2–92.8] | 68.8 [63.9–73.9] | |
| Sweden | ||||||
| MSM | … | … | 98.4 | 92.2 | … | |
| PWID | … | … | 93.4 | 87.8 | … | |
| Heterosexuals | … | … | 96.0 | 91.6 | … | |
| Men | … | … | 96.9 | 91.3 | … | |
| Women | … | … | 96.2 | 92.1 | … | |
| Total | 8,098 [8,143–8,061] | 89.2 [88.8–89.6] | 96.6 | 91.6 | … | |
| United Kingdom | ||||||
| MSM | 48 800 [46 400–53 600] | 88.0 [80.0–92.0] | 97.0 | 93.5 [90.0–97.0] | 79.3 [76.2–82.4] | |
| PWID | 2,500 [2,300–2,800] | 75.0 [67.0–81.0] | 93.0 | 88.0 [83.0–93.0] | 61.0 [57.6–64.5] | |
| Heterosexuals | 49 900 [49 100–51 700] | 91.0 [88.0–93.0] | 96.0 | 91.9 [87.0–96.0] | 79.9 [76.0–78.8] | |
| Men | 70 500 [67 800–75 400] | 90.0 [84.0–94.0] | 96.0 | 93.0 [89.0–97.0] | 80.4 [77.0–78.8] | |
| Women | 30 900 [30 300–31 700] | 92.0 [90.0–94.0] | 95.0 | 91.7 [87.0–96.0] | 80.5 [76.5–84.4] | |
| Total | 101 400 [98 600–106 400] | 91.0 [86.0–93.0] | 96.0 | 92.5 [88.0–97.0] | 80.4 [76.8–84.0] | |
| All countriesc | ||||||
| MSM | 303 203 | 86.0 [81.0–89.0] | 93.0 (91.0–95.0) | 93.0 [90.0–96.0] | 73.8 [71.5–76.1] | |
| PWID | 74 007 | 94.0 [91.0–96.0] | 88.0 [83.0–93.0] | 85.0 [78.0–91.0] | 69.6 [64.2–75.1] | |
| Heterosexuals | 269 571 | 86.0 [84.0–89.0] | 92.0 [91.0–94.0] | 91.0 [88.0–93.0] | 72.5 [70.1–73.9] | |
| Men | 516 064 | 87.0 [83.0–90.0] | 92.0 [90.0–94.0] | 92.0 [88.0–95.0] | 73.0 [70.3–75.5] | |
| Women | 176 560 | 89.0 [92.0–94.0] | 92.0 [90.0–94.0] | 89.0 [86.0–93.0] | 73.2 [70.2–76.2] | |
| Total | 702 848 | 87.0 [84.0–90.0] | 92.0 [90.0–94.0] | 91.0 [88.0–94.0] | 73.2 [70.7–75.7] |
Percentages correspond to proportions of individuals out of the previous stage, except for the last column where the percentage suppressed out of the total PLHIV is presented.
Abbreviations: CI, confidence interval; MSM, men who have sex with men; PLHIV, people living with human immunodeficiency virus; PWID, people who inject drugs.
aHIV-RNA measurement ≤200 copies/mL at last visit.
bNon-MSM, non-PWID, that is, mainly people presumed to have acquired HIV via sex between men and women.
cBased on available data: for Croatia only overall estimates and estimates for MSM were produced, and for Sweden only overall estimates were produced. The range of the number of PLHIV was not estimated since not all countries have provided lower and upper estimates. For stages 2–4, ranges were estimated based on available data.